[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"15e7f739-98b7-4cb1-a7f5-0dfc757321cf","acronym":"NCI-2020-01520","url":"https://clinicaltrials.gov/study/NCT04348747","created_at":"2021-01-18T21:02:18.854Z","updated_at":"2024-07-02T16:34:26.116Z","phase":"Phase 2","brief_title":"Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","source_id_and_acronym":"NCT04348747 - NCI-2020-01520","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HER-2 negative","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-14"},{"id":"acb3cec9-0b88-4c6f-817b-e0033a486f8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03734692","created_at":"2024-06-08T04:12:57.198Z","updated_at":"2025-02-25T16:08:36.350Z","phase":"Phase 1/2","brief_title":"Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03734692","lead_sponsor":"Robert Edwards","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Ampligen (rintatolimod)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/28/2019","start_date":" 01/28/2019","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-05"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"8e13ae6f-2afc-43dc-b06c-933f9e190424","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093323","created_at":"2023-11-30T22:15:48.537Z","updated_at":"2024-07-02T16:35:00.203Z","phase":"Phase 2","brief_title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","source_id_and_acronym":"NCT04093323","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 08/22/2025","primary_completion_date":" 08/22/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-30"},{"id":"59bdfa97-7b2e-46bf-97c1-23ab33821d5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081389","created_at":"2021-01-18T19:59:01.001Z","updated_at":"2024-07-02T16:35:37.452Z","phase":"Phase 1","brief_title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT04081389","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 02/27/2023","study_completion_date":" 02/27/2023","last_update_posted":"2023-09-11"},{"id":"112a8f53-b48b-4fcf-ab56-3185a8febfbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379518","created_at":"2021-01-18T21:09:01.336Z","updated_at":"2024-07-02T16:35:53.963Z","phase":"Phase 1/2","brief_title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","source_id_and_acronym":"NCT04379518","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod)"],"overall_status":"Suspended","enrollment":" Enrollment 64","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 11/17/2023","primary_completion_date":" 11/17/2023","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-03-06"},{"id":"2ef799d3-1ede-4380-b63e-812810bb7c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03403634","created_at":"2021-01-18T16:47:42.513Z","updated_at":"2024-07-02T16:36:16.175Z","phase":"Phase 2a","brief_title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","source_id_and_acronym":"NCT03403634","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • MSI • CD8","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["PD-L1 • MSI • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/23/2020","primary_completion_date":" 12/23/2020","study_txt":" Completion: 08/29/2021","study_completion_date":" 08/29/2021","last_update_posted":"2022-03-02"},{"id":"d160bba2-646c-4438-b590-5eb0c74d7442","acronym":"","url":"https://clinicaltrials.gov/study/NCT02151448","created_at":"2021-01-18T09:59:55.040Z","updated_at":"2024-07-02T16:36:43.024Z","phase":"Phase 1/2","brief_title":"αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies","source_id_and_acronym":"NCT02151448","lead_sponsor":"David Bartlett","biomarkers":" IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/18/2019","primary_completion_date":" 02/18/2019","study_txt":" Completion: 02/18/2019","study_completion_date":" 02/18/2019","last_update_posted":"2020-07-20"},{"id":"7ec4dc43-23fc-4cf6-bad6-c9e36b3d162c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01355393","created_at":"2021-01-18T05:32:33.668Z","updated_at":"2024-07-02T16:36:50.276Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer","source_id_and_acronym":"NCT01355393","lead_sponsor":"University of Washington","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ampligen (rintatolimod) • HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2020-02-10"},{"id":"284ff763-35c2-4324-a098-fcf67bc5ba64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02615574","created_at":"2021-01-18T12:42:48.078Z","updated_at":"2024-07-02T16:37:17.536Z","phase":"Phase 2","brief_title":"A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02615574","lead_sponsor":"Pawel Kalinski","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • HLA-A2 positive","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-09-26"}]